I-Mab Logo
Contact Us For inquiries, get in touch with our team
  • Who We Are

    A global innovative biotech company

  • Value Creation

    Laser-focused on delivering innovative therapies to patients in need

  • Leadership Team

    A world-class global leadership team

  • People and Culture

    People are the cornerstone of our success

  • Commitment to ESG

    Committed to the highest environmental, social and governance standard

  • Science

    Our cutting-edge science focuses on fine-tuning the immune network in cancer

  • Operations

    An integrated research, development, manufacturing and commercialisation strategy

  • Publications & Presentations

    A compilation of our latest publications and presentations

  • Pipeline

    We have an innovative and advanced immuno-oncology clinical pipeline

  • Clinical Trials

    We work closely with global investigators to carefully conduct and monitor clinical studies

  • Partnerships

    We partner to deliver innovative medicines that transform patients' lives

  • News
  • Events
  • Mission and Values
  • Highlights
  • Global Footprint
  • Awards
  • Value Creation Model
  • Value Creation Enabler
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Employee Development
  • Employee Wellness
  • Diversity, Inclusion and Equity
  • T+ Excellent Employer Award
  • Patients
  • Philanthropy
  • People
  • ESG Policies
  • Unmet Needs
  • Cutting-Edge Science
  • Key Products
  • Lemzoparlimab (TJC4)
  • Uliledlimab (TJD5)
  • Givastomig (TJ-CD4B)
  • Efineptakin alfa (TJ107)
  • TJ-C64B
  • Enoblituzumab (TJ271)
  • TJ-C4GM
  • TJ-L1I7
  • Hematologic Malignancies
  • Solid Tumors
  • Other Assets
  • Putting Patients First
  • Advancing Clinical Research
  • Selected Ongoing Clinical Trials
  • Strategic Partnering Model
  • Landmark Deals
  • Our Partners
  • Press Releases
  • Media Reports
  • Partner News
About Innovation Products Partnerships Newsroom
Investors Careers Contact Us
  • 中
I-Mab Logo
  • About
    • Who We Are
    • Value Creation
    • Leadership Team
    • People and Culture
    • Commitment to ESG
  • Innovation
    • Science
    • Operations
    • Publications & Presentations
  • Products
    • Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • 中

Partner News

  • Press Releases
  • Media Reports
  • Partner News

2023.05.25

HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy

2023.04.11

HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

2021.06.29

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

2020.11.09

Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer

2020.06.22

Genexine, “Hyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients”

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News & Events
  • Investors
  • Careers
  • Contact
  • 中

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2023 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号